2018
DOI: 10.1158/1535-7163.mct-17-0290
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

Abstract: The cyclinD:CDK4/6:Rb axis is dysregulated in a variety of human cancers.Targeting this pathway has proven to be a successful therapeutic approach in ER+ breast cancer. In this study, in vitro and in vivo preclinical breast cancer models were used to investigate the expanded use of the CDK4/6 inhibitor, abemaciclib.Using a panel of 44 breast cancer cell lines, differential sensitivity to abemaciclib was observed and was seen predominately in the luminal ER+/HER2-and ER+/HER2+ subtypes. However, a subset of tri… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

7
66
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 84 publications
(73 citation statements)
references
References 47 publications
7
66
0
Order By: Relevance
“…Furthermore, acute deletion of cyclin D1 or inhibition of CDK4/6 kinase activity using palbociclib blocked progression of HER2-driven breast cancer in mice 18 . Similar to palbociclib, abemaciclib was recently shown to exhibit substantial activity against luminal ER-positive HER2-positive breast cancer cells both in vitro and in xenografts 64 . Its activity was further enhanced in combination with HER2-targeted therapy 64 .…”
Section: Cdk4/6 Inhibitors In Her2-positive Breast Cancermentioning
confidence: 99%
See 4 more Smart Citations
“…Furthermore, acute deletion of cyclin D1 or inhibition of CDK4/6 kinase activity using palbociclib blocked progression of HER2-driven breast cancer in mice 18 . Similar to palbociclib, abemaciclib was recently shown to exhibit substantial activity against luminal ER-positive HER2-positive breast cancer cells both in vitro and in xenografts 64 . Its activity was further enhanced in combination with HER2-targeted therapy 64 .…”
Section: Cdk4/6 Inhibitors In Her2-positive Breast Cancermentioning
confidence: 99%
“…Similar to palbociclib, abemaciclib was recently shown to exhibit substantial activity against luminal ER-positive HER2-positive breast cancer cells both in vitro and in xenografts 64 . Its activity was further enhanced in combination with HER2-targeted therapy 64 .…”
Section: Cdk4/6 Inhibitors In Her2-positive Breast Cancermentioning
confidence: 99%
See 3 more Smart Citations